300453.SZ
Jiang Xi Sanxin Medtec Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 9.72
−1.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.6B | 1.5B | 1.3B | 1.3B |
| Cost of Revenue | 1.1B | 1.0B | 970.3M | 846.5M | 887.0M |
| Gross Profit | 617.8M | 590.9M | 530.1M | 453.6M | 449.0M |
| Operating Expenses | |||||
| R&D Expense | 76.8M | 75.3M | 64.0M | 51.1M | 40.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 123.3M | 122.6M | 108.0M | 91.4M | 103.9M |
| Selling & Marketing Expense | 80.1M | 77.9M | 84.1M | 78.3M | 89.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 299.6M | 292.1M | 267.1M | 229.3M | 242.2M |
| Cost and Expenses | 1.4B | 1.3B | 1.2B | 1.1B | 1.1B |
| Operating Income (EBIT) | 345.2M | 325.4M | 278.8M | 257.6M | 230.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 344.9M | 324.2M | 276.1M | 252.8M | 225.6M |
| Income Tax Expense | 38.6M | 34.0M | 28.4M | 29.5M | 26.5M |
| Bottom Line | |||||
| Net Income | 279.6M | 264.9M | 227.4M | 206.6M | 184.6M |
| Earnings from Cont. Ops | 306.3M | 290.3M | 247.7M | 223.2M | 199.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 279.6M | 264.9M | 227.4M | 206.6M | 184.6M |
| Per Share | |||||
| Basic EPS | CN¥0.54 | CN¥0.51 | CN¥0.44 | CN¥0.40 | CN¥0.36 |
| Diluted EPS | CN¥0.54 | CN¥0.51 | CN¥0.44 | CN¥0.40 | CN¥0.36 |
| Revenue Per Share | CN¥3.26 | CN¥3.17 | CN¥2.91 | CN¥2.51 | CN¥2.59 |
| Shares | |||||
| Basic Shares Outstanding | 517.9M | 517.8M | 515.0M | 518.3M | 515.0M |
| Diluted Shares Outstanding | 517.9M | 517.8M | 515.0M | 518.3M | 515.0M |
| Profitability Metrics | |||||
| EBITDA | — | 446.8M | 368.7M | 334.2M | 298.9M |
| D&A | — | 121.4M | 89.9M | 76.5M | 68.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026